List of architectural magazines published in Japan Japanese reign names Year founded Final year Title of magazine (Translation) Publisher Text Language Location Coverage Figure Japanese English Japan ...Int'l Displayed Meiji era: 1868-1912 1881 1884→ Kogaku-Soshi (Journal of the Engineering Society) Yushodo-Shoten ○ - - - 1884 1921 Kogaku-Kwai-shi (Journal of the Engineering Society) Kogakukai (Federation of Engineering Societies) ○ × ○ ○ A 1887 Existing Journal of Architecture and Building Science Architectural Institute of Japan ○ × ○ ○ B-D 1900 1975 Kentiku (Architecture) Seidoh-sha (after June 1961) ○ × ○ ○ E Taisho era: 1912-1926 1907 1944 Kentiku Sekai (Architectural World) Kenchiku Sekai, Inc. ○ × ○ × F Showa era: 1926-1989 1925 1927→ Kokusaikentiku-Jiron (International Architecture) kokusai-kentiku-Kyokai ○ × ○ ○ 1925 Existing Shinkentiku→Shinkenchiku (Japan Architect) Shinkenchiku-sha Co., Ltd. ○ × ○ ○ G-I Great Kanto Earthquake: 1923 1928 1967 Kokusaikentiku (International Architecture) BIJUTSU SHUPPAN-SHA Ltd. ○ × ○ ○ J-M WW II - 1941-45 1946 2004 Kenchiku Bunka (Architectural Culture) SHOKOKUSHA Publishing Co., Ltd. ○ × ○ × N 1946 1988 Shinjutaku Shinjutakusha ○ × ○ × 1946 Existing Kindai Kenchiku (Contemporary Architecture of the World) KINDAIKENCHIKU-SHA Co., Ltd. ○ × ○ ▵ 1950 Existing Kenchiku Gijutsu (Kenchiku Gijutsu) Kenchikugijutsu, Inc. ○ × ○ × O 1951 Existing Modern Living HEARST FUJINGAHO ○ × ○ ○ P, Q 1955 2006 Shitsunai (The Magazine of Interior Design) KOUSAKUSHA ○ × ○ × 1956 1991→ JA (Japan Architect) monthly Shinkenchiku-sha Co., Ltd. × ○ ○ × R-V 1956 Existing Shoten Kenchiku (Store Design/Interior/Architecture) SHOTENKENCHIKU-SHA Publishing Co., Ltd. ○ × ○ × 1958 Existing Kenchiku-Chishiki (Architectural Knowledge) X-knowledge Co., Ltd. ○ × ○ × 1958 Existing Kateigaho International Japan Edition SEKAI BUNKA PUBLISHING INC. ○ ○ ○ × Tokyo Olympic Games 1964 1964 Existing DETAIL SHOKOKUSHA Publishing Co., Ltd. ○ × ○ × 1964 Existing SD (Space Deign) Kajima Institute Publishing Co., Ltd. ○ × ○ ○ 1966 Existing Kenchiku Gahou (Visual Architecture) Kenchiku Gahou Inc. ○ × ○ × 1968 1986 Toshi Jutaku Kajima Institute Publishing Co., Ltd. ○ × ○ ○ Osaka World Fair 1970 1970 1999 GA (Global Architecture) A.D.A.EDITA Tokyo ○ ○ × ○ W, X 1971 Existing a+u (Architecture and Urbanism) A+U Publishing Co., Ltd., Shinkenchiku-sha ○ ○ × ○ Y, Z 1975 Existing Jutaku Kenchiku (a monthly journal for home builders and designers) Kenchiku Shiryo Kenkyusha Co., Ltd. ○ × ○ × 1976 Existing GA Houses A.D.A.EDITA Tokyo ○ ○ ○ ○ 1976 Existing Nikkei Architecture Nikkei Business Publications,Inc. ○ × ○ × 1980 Existing GA Document A.D.A.EDITA Tokyo ○ ○ ○ ○ 1985 Existing JT / Jutaku Tokushu Shinkenchiku-sha Co., Ltd. ○ × ○ × Heisei era: 1989 - current 1991 Existing JA (Japan Architect) quarterly Shinkenchiku-sha Co., Ltd. ○ ○ ○ × 1992 Existing GA Japan A.D.A.EDITA Tokyo ○ ○ ○ × 1994 2008 10+1 (Ten Plus One) LIXIL Corporation ○ × ○ ○ 2000 Existing 10+1 web site LIXIL Corporation ○ × ○ ○ Since the Meiji Restoration of 1868 architectural education in Japan was for the first time influenced by European and American design practice and its architects. The first architectural magazine, “Kogakusosho (Engineering Book)” was released in 1881, followed by the “Journal of Architecture and Building Science” published by the predecessor of the AIJ from 1887; “Kentiku (Architecture)” was published in 1900, and “Kentiku-Sekai (Architectural World)” was published in 1907. (A) Kogaku-Kwai-shi, 1890, cover; (B) Journal of Architecture and Building Science, 1889, cover; (C) Journal of Architecture and Building Science, 1889, pp. 2, 3; (D) Journal of Architecture and Building Science, 1951, cover (from Shoji HAYASHI Library: SHL); (E) Kentiku, November 1962, cover (from SHL); (F) Kentiku-Sekai, June 1937, cover; (G) Sinkentiku, August 1934, cover (from SHL); (H) Sinkentiku, August 1934, contents (from SHL); (I) Sinkentiku, August 1934, article, p. 117 (from SHL); (J) Kokusaikentiku, April 1951, cover (from SHL); (K) Kokusaikentiku, April 1951, contents (from SHL); (L) Kokusaikentiku, November, 1955, cover; (M) Kokusaikentiku, November, 1955, Hodgson House, Philip Johnson, pp. 20, 21; (N) Kenchiku-Bunka, December, 1948, cover (from SHL); (O) Kenchiku-Gijutsu, July 1950, cover (from Kenchiku-Gijutsu Library); (P) Modern Living, December, 1948, cover (from SHL); (Q) Modern Living, May 1957, cover (from SHL); (R) JA, June 1959, cover; (S) JA, Feburuary 1963, cover; (T) JA, November-December, 1983, cover; (U) JA, article: “After Modernism” A Dialogue between Kenzo TANGE and Kazuo SHINOHARA, November-December, 1983, p. 7; (V) JA, May 1988, cover; (W) GA, May 1988, cover; (X) GA, May 1988, cover; (Y) a+u, January 1970, cover; (Z) a+u, January 1970, contents. “Shinkenchiku,” in particular, has proven the most influential architectural magazine in the professional milieu over the long term, having covered all categories of architecture, including individual dwellings which are typical of Japanese architecture, of interest to broader Japanese architectural society.
Abstract
Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. A breakthrough in cancer ...immunotherapy employing immune checkpoint inhibitors has evolved into a number of clinical trials with antibodies against programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for patients with squamous cell carcinoma of the head and neck. CheckMate141 and KEYNOTE-048 were practice-changing randomized phase 3 trials for patients with platinum-refractory and platinum-sensitive recurrent or metastatic squamous cell carcinoma of the head and neck, respectively. Furthermore, many combination therapies using anti-CTLA-4 inhibitors, tyrosine kinase inhibitors and immune accelerators are currently under investigation. Thus, the treatment strategy of recurrent or metastatic squamous cell carcinoma of the head and neck is becoming more heterogeneous and complicated in the new era of individualized medicine. Ongoing trials are investigating immunotherapeutic approaches in the curative setting for locoregionally advanced disease. This review article summarizes knowledge of the role of the immune system in the development and progression of squamous cell carcinoma of the head and neck, and provides a comprehensive overview on the development of immunotherapeutic approaches in both recurrent/metastatic and locoregionally advanced diseases.
Purpose
To investigate 24-month results of intravitreal aflibercept (IVA) for macular edema due to branch retinal vein occlusion (BRVO-ME).
Study design
Retrospective study.
Methods
Subjects were ...treatment-naïve BRVO-ME patients at the Ophthalmology Department of Juntendo University Urayasu Hospital from November 2015 to March 2017 who received IVA treatment for 24 months. After the first injection, reinjection was performed as needed when ME had recurred or was prolonged beyond 300 μm. Data included changes in best corrected visual acuity and central foveal thickness, total number of injections, and the case background factors that required reinjection after 12 months. ME remission was defined as patients without additional injections for 6 months.
Results
Forty eyes of 40 patients (64.5 ± 11.5 years), 21 men and 19 women, were included. Average best corrected visual acuity and central foveal thickness at baseline were logMAR 0.42 ± 0.21, 601.4 ± 181.3 μm, logMAR 0.08 ± 0.25, 214.6 ± 62.7 μm at 12 months, logMAR 0.02 ± 0.16, 216.6 ± 97.8 μm at 24 months, all significantly improved from baseline. The average number of injections was 2.2 ± 1.0 times in the first year and 0.4 ± 0.8 times in the second year. The rate of ME remission was 60.0% at 12 months and 87.5% at 24 months. Period between onset and injections was significantly associated with reinjection after 12 months (p =.030).
Conclusions
IVA was effective over 24 months for ME due to BRVO in many cases. Early injection treatment may reduce the need for later injections.
Background
Online adaptation during intensity‐modulated proton therapy (IMPT) can minimize the effect of inter‐fractional anatomical changes, but remains challenging because of the complex workflow. ...One approach for fast and automated online IMPT adaptation is dose restoration, which restores the initial dose distribution on the updated anatomy. However, this method may fail in cases where tumor deformation or position changes occur.
Purpose
To develop a fast and robust IMPT online adaptation method named “deformed dose restoration (DDR)” that can adjust for inter‐fractional tumor deformation and position changes.
Methods
The DDR method comprises two steps: (1) calculation of the deformed dose distribution, and (2) restoration of the deformed dose distribution. First, the deformable image registration (DIR) between the initial clinical target volume (CTV) and the new CTV were performed to calculate the vector field. To ensure robustness for setup and range uncertainty and the ability to restore the deformed dose distribution, an expanded CTV‐based registration to maintain the dose gradient outside the CTV was developed. The deformed dose distribution was obtained by applying the vector field to the initial dose distribution. Then, the voxel‐by‐voxel dose difference optimization was performed to calculate beam parameters that restore the deformed dose distribution on the updated anatomy. The optimization function was the sum of total dose differences and dose differences of each field to restore the initial dose overlap of each field. This method only requires target contouring, which eliminates the need for organs at risk (OARs) contouring. Six clinical cases wherein the tumor deformation and/or position changed on repeated CTs were selected. DDR feasibility was evaluated by comparing the results with those from three other strategies, namely, not adapted (continuing the initial plan), adapted by previous dose restoration, and fully optimized.
Results
In all cases, continuing the initial plan was largely distorted on the repeated CTs and the dose‐volume histogram (DVH) metrics for the target were reduced due to the tumor deformation or position changes. On the other hand, DDR improved DVH metrics for the target to the same level as the initial dose distribution. Dose increase was seen for some OARs because tumor growth had reduced the relative distance between CTVs and OARs. Robustness evaluation for setup and range uncertainty (3 mm/3.5%) showed that deviation in DVH‐bandwidth for CTV D95% from the initial plan was 0.4% ± 0.5% (Mean ± S.D.) for DDR. The calculation time was 8.1 ± 6.4 min.
Conclusions
An online adaptation algorithm was developed that improved the treatment quality for inter‐fractional anatomical changes and retained robustness for intra‐fractional setup and range uncertainty. The main advantage of this method is that it only requires target contouring alone and saves the time for OARs contouring. The fast and robust adaptation method for tumor deformation and position changes described here can reduce the need for offline adaptation and improve treatment efficiency.
The role of adjuvant external-beam radiotherapy (EBRT) for locally advanced differentiated thyroid cancer (DTC) is controversial because of the lack of prospective data. To prepare for a clinical ...trial, this study investigated the current clinical practice of adjuvant treatments for locally advanced DTC. A survey on treatment selection criteria for hypothetical locally advanced DTC was administered to representative thyroid surgeons of facilities participating in the Japan Clinical Oncology Group Radiation Therapy Study Group. Of the 43 invited facilities, surgeons from 39 (91%) completed the survey. For R1 resection or suspected residual disease, 26 (67%) facilities administered high-dose (100–200 mCi) radioactive iodine (RAI), but none performed EBRT. For R2 resection or unresectable primary disease, 26 (67%) facilities administered high-dose RAI and 7 (18%) performed adjuvant treatments, including EBRT. For complete resection with nodal extra-capsular extension, 13 (34%) facilities administered high-dose RAI and 1 (3%) performed EBRT. For unresectable mediastinal lymph node metastasis, 31 (79%) facilities administered high-dose RAI and 5 (13%) performed adjuvant treatments, including EBRT. Adjuvant EBRT was not routinely performed mainly because of the lack of evidence for efficacy (74%). Approximately 15% of the facilities routinely considered adjuvant EBRT for DTC with R2 resection or unresectable primary or lymph node metastasis disease. Future clinical trials will need to optimize EBRT for these patients.
Abstract
In order to maximize the benefit of induction chemotherapy, practice based on a comprehensive interpretation of a large number of clinical trials, as in this review, is essential. The ...standard treatment for locally advanced squamous cell carcinoma of the head and neck is surgery or chemoradiation. However, induction chemotherapy followed by (chemo) radiotherapy may be used in some circumstances. Although many clinical trials of induction chemotherapy have been conducted, a rationale other than to preserve the larynx is still controversial. Selection of this modality should therefore be made with care. The current standard regimen for induction chemotherapy is docetaxel, cisplatin and 5-FU, but concerns remain about toxicity, cost and the duration of treatment. Regarding treatment after induction chemotherapy, it is also unclear whether radiation alone or chemoradiation is the better option. Furthermore, there is no answer as to what drugs should be used in combination with radiation therapy after induction chemotherapy. Several new induction chemotherapy treatment developments are currently underway, and future developments are expected. This review article summarizes the current position of induction chemotherapy for head and neck squamous cell carcinoma, based on the evidence produced to date, and discusses the future prospects for this treatment.
Induction chemotherapy is one of the organ preservation strategies for laryngeal and hypopharyngeal cancers, but its role for unresectable locally advanced squamous cell carcinoma of the head and neck is controversial.
Tracheal suctioning is an important procedure to maintain airway patency by removing secretions. Today, suctioning operators include not only medical staff, but also family caregivers. The use of a ...simulation system has been noted to be the most effective way to learn the tracheal suctioning technique for operators. While the size of the trachea varies across different age groups, the artificial trachea model in the simulation system has only one fixed model. Thus, this study aimed to construct multiple removable trachea models according to different age groups. We enrolled 20 patients who had previously received proton beam therapy in our institution and acquired the treatment planning computed tomography (CT) image data. To construct the artificial trachea model for three age groups (children, adolescents and young adults, and adults), we analyzed the three-dimensional coordinates of the entire trachea, tracheal carina, and the end of the main bronchus. We also analyzed the diameter of the trachea and main bronchus. Finally, we evaluated the accuracy of the model by analyzing the difference between the constructed model and actual measurements. The trachea model was 8 cm long for children and 12 cm for adolescents and young adults, and for adults. The angle between the trachea and bed was about 20 degrees, regardless of age. The mean model accuracy was less than 0.4 cm. We constructed detachable artificial trachea models for three age groups for implementation in the endotracheal suctioning training environment simulator (ESTE-SIM) based on the treatment planning CT image. Our constructed artificial trachea models will be able to provide a simulation environment for various age groups in the ESTE-SIM.
Background This study aimed to assess the utility of deep learning analysis using pretreatment FDG-PET images to predict local treatment outcome in oropharyngeal squamous cell carcinoma (OPSCC) ...patients. Methods One hundred fifty-four OPSCC patients who received pretreatment FDG-PET were included and divided into training (n = 102) and test (n = 52) sets. The diagnosis of local failure and local progression-free survival (PFS) rates were obtained from patient medical records. In deep learning analyses, axial and coronal images were assessed by three different architectures (AlexNet, GoogLeNET, and ResNet). In the training set, FDG-PET images were analyzed after the data augmentation process for the diagnostic model creation. A multivariate clinical model was also created using a binomial logistic regression model from a patient's clinical characteristics. The test data set was subsequently analyzed for confirmation of diagnostic accuracy. Assessment of local PFS rates was also performed. Results Training sessions were successfully performed with an accuracy of 74-89%. ROC curve analyses revealed an AUC of 0.61-0.85 by the deep learning model in the test set, whereas it was 0.62 by T-stage, 0.59 by clinical stage, and 0.74 by a multivariate clinical model. The highest AUC (0.85) was obtained with deep learning analysis of ResNet architecture. Cox proportional hazards regression analysis revealed deep learning-based classification by a multivariate clinical model (P < .05), and ResNet (P < .001) was a significant predictor of the treatment outcome. In the Kaplan-Meier analysis, the deep learning-based classification divided the patient's local PFS rate better than the T-stage, clinical stage, and a multivariate clinical model. Conclusions Deep learning-based diagnostic model with FDG-PET images indicated its possibility to predict local treatment outcomes in OPSCCs. Keywords: Deep learning, Oropharyngeal squamous cell carcinoma, FDG-PET, Treatment outcome
Objective
Silicon photomultiplier-based positron emission tomography/computed tomography (SiPM-PET/CT) has the superior spatial resolution to conventional PET/CT (cPET/CT). This head-to-head ...comparison study compared the images of physiological
18
F-fluorodeoxyglucose (FDG) accumulation in small-volume structures between SiPM-PET/CT and cPET/CT in patients scanned with both modalities, and we investigated whether the thresholds that are reported to be useful for differentiating physiological accumulations from malignant lesions can also be applied to SiPM-PET/CT.
Methods
We enrolled 21 consecutive patients with head and neck malignancies who underwent whole-body FDG-PET/CT for initial staging or a follow-up evaluation (October 2020 to March 2022). After being injected with FDG, all patients underwent PET acquisition on both Vereos PET-CT and Gemini TF64 PET-CT systems (both Philips Healthcare) in random order. For each patient, the maximum standardized uptake value (SUVmax) was measured in the pituitary gland, esophagogastric junction (EGJ), adrenal glands, lumbar enlargement of the spinal cord, and epididymis. We measured the liver SUVmean and the blood pool SUVmean to calculate the target-to-liver ratio (TLR) and the target-to-blood ratio (TBR), respectively. Between-groups differences in each variable were examined by a paired t-test. We also investigated whether there were cases of target uptake greater than the reported threshold for distinguishing pathological from physiological accumulations.
Results
Data were available for 19 patients. Ten patients were in Group 1, i.e., the patients who underwent SiPM-PET first, and the remaining nine patients who underwent cPET first were in Group 2. In the SiPM-PET results, the SUVmax of all targets was significantly higher than that obtained by cPET in all patients, and this tendency was also observed when the patients were divided into Groups 1/2. The TLRs of all targets were significantly higher in SiPM-PET than in cPET in all patients, and SiPM-PET also showed significantly higher TBRs for all targets except the EGJ (
p
= 0.052).
Conclusions
The physiological uptake in the small structures studied herein showed high accumulation on SiPM-PET. Our results also suggest that the thresholds reported for cPET to distinguish pathological accumulations likely lead to false-positive findings in SIPM-PET evaluations.
PDF
